Magnetic resonance imaging use is increasing in routine preoperative evaluation of women with breast cancer
the ONA take:
A population-based retrospective cohort study was conducted to determine patterns in the utilization of preoperative breast magnetic resonance imaging (MRI) in a health care system with universal insurance.
Breast MRI is commonly used in preoperative evaluation of women with breast cancer despite the existing literature showing the practice has little benefit for most patients.
Using administrative heath care databases in Ontario, Canada, the study included 53,015 patients with primary operable breast cancer treated from 2003 to 2012 in more than 14 geographic regions.
Primary outcomes were defined as use of preoperative breast MRI by year, geographic region, and breast cancer stage. In addition, the researchers evaluated postdiagnosis imaging, biopsy, and short-term surgical outcomes between those who did and did not receive MRI.
The study results indicate that 14.8% of patients had a preoperative MRI, and its use increased across all stages by 8-fold. The researchers report that preoperative breast MRI is associated with a significant increase in ancillary investigations, wait time to surgery, mastectomies, and contralateral prophylactic mastectomies.
Study to determine patterns in the utilization of preoperative breast magnetic resonance imaging (MRI) in a health care system with universal insurance.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|